Acinetobacter is a genus of bacteria that can serve as an important marker for gut microbiome analysis. Typically found in soil and water environments, certain species of Acinetobacter have adapted to the human gut. While Acinetobacter is a minor component of the normal gut flora, its presence and levels can be of clinical interest. In a healthy individual, Acinetobacter exists in low concentrations and is part of the diverse microbial ecosystem. However, in certain contexts, an overgrowth of Acinetobacter can be associated with dysbiosis, a microbial imbalance that may contribute to various health issues. This genus includes species like Acinetobacter baumannii, known for its antibiotic resistance and relevance in hospital-acquired infections, but its role within the gut microbiome is less aggressive and more commensal. Elevated levels may suggest a disruption in the normal gut flora, possibly due to factors like antibiotic use, dietary changes, or underlying gastrointestinal disorders. Conversely, low levels typically do not raise concern and align with a balanced gut microbiome.
rarely a cause of disease in humans
Mitochondrial marker / krebs cycle metabolite
Mitochondrial marker / krebs cycle metabolite
Mitochondrial marker / krebs cycle metabolite
Mitochondrial marker / krebs cycle metabolite
Mitochondrial marker / krebs cycle metabolite
Pituitary hormone
Actin (Smooth Muscle) Antibodies (ASMA; anti-F-actin) are autoantibodies that target proteins in smooth muscle and are most strongly linked to autoimmune hepatitis (AIH), especially type 1, though they can also appear in chronic active hepatitis and, less commonly, in primary biliary cholangitis (PBC). Positivity is reported in about 52–85% of people with AIH or chronic active hepatitis and about 22% with PBC, and ASMA often occurs together with ANA and elevated IgG, forming a characteristic autoimmune profile. Doctors order this test mainly to help identify AIH when liver enzymes (ALT, AST) are high, rule out other causes of liver disease, and distinguish between AIH, PBC, and other conditions. A negative result (0–19) does not support AIH on its own, a weak positive (20–30) suggests possible autoimmune activity that needs to be interpreted alongside other blood tests, imaging, and symptoms, and a moderate-to-strong positive (>30) provides stronger support for AIH, though a full diagnostic assessment and sometimes a liver biopsy are required. While antibody levels can decline with treatment, changes in titers are not reliable for monitoring, so doctors primarily track liver enzymes, bilirubin, IgG, and symptoms. If positive, further testing may include antibody panels (ANA, AMA, anti-LKM-1, anti-SLA), viral hepatitis screening, imaging, and in some cases a biopsy; if AIH is confirmed, treatment often involves immunosuppressive medications (such as corticosteroids with or without azathioprine) to reduce inflammation and prevent fibrosis or cirrhosis.
Related to autoimmune hepatitis
Autoimmune smooth muscle marker
one of the largest bacterial phyla
Actinobacteriota, formerly known as Actinobacteria, is a significant phylum within the gut microbiota that plays a crucial role in human health. On an adult gut health test, Actinobacteriota serves as a marker for assessing various aspects of gut function, including digestion, immune regulation, and the production of beneficial metabolites. This phylum is well known for containing bacterial genera such as Bifidobacterium, which are associated with positive health outcomes, including the production of short-chain fatty acids (SCFAs), modulation of inflammation, and inhibition of harmful pathogens. One of the primary functions of Actinobacteriota in the gut is its involvement in carbohydrate metabolism. Many species within this group are adept at breaking down complex carbohydrates and fibers, which are not digestible by human enzymes, into SCFAs like acetate and butyrate. These metabolites serve as an energy source for colon cells, help maintain the integrity of the gut lining, and contribute to a balanced inflammatory response. Therefore, a healthy level of Actinobacteriota on a gut health test is often seen as indicative of a diet rich in fiber and prebiotics, which supports overall gut health. However, an imbalance in Actinobacteriota levels can be a marker of gut dysbiosis, a condition where the microbial community in the gut is disturbed. Low levels of beneficial bacteria like Bifidobacterium may indicate poor digestion of fiber, reduced SCFA production, and a higher risk of inflammatory conditions such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). Conversely, an overgrowth of certain Actinobacteriota species, particularly pathogenic strains, could be associated with conditions like small intestinal bacterial overgrowth (SIBO) or contribute to metabolic disorders. In conclusion, Actinobacteriota is a key marker on adult gut health tests that provides valuable insights into digestive health, microbial balance, and overall well-being. Maintaining a balanced level of this microbial group is essential for optimal gut function and health.
Commensal oral–gut bacterium
considered low abundance colonizers of the GI tract with primary residence on the skin.
Activated CD21low CD38- % The Activated CD21low CD38- % biomarker measures the proportion of B cells in the bloodstream characterized by low expression of CD21 (complement receptor 2) and absence of CD38 (a marker of activation and differentiation). These cells represent a subset of atypical or activated B cells, often associated with immune dysregulation, chronic activation, or pathological conditions. Understanding CD21low CD38- B Cells CD21 (Complement Receptor 2): A protein expressed on mature B cells that facilitates immune responses by interacting with complement-coated antigens. Reduced CD21 expression may indicate immune activation or dysregulation. CD38: A multifunctional protein involved in cell activation and differentiation. CD38- B cells are typically less activated or belong to distinct B cell subsets. Phenotype: CD21low CD38- B cells are often considered atypical or exhausted B cells, reflecting chronic immune activation or exposure to persistent antigens. Clinical Significance of Activated CD21low CD38- % Chronic Immune Activation: Elevated levels are associated with prolonged immune system activation, commonly seen in chronic infections such as: HIV Hepatitis B and C Epstein-Barr Virus (EBV) Autoimmune Diseases: Increased proportions of CD21low CD38- B cells are linked to autoimmune conditions, such as: Systemic lupus erythematosus (SLE) Rheumatoid arthritis (RA) Sjögren’s syndrome B Cell Exhaustion: Persistent antigen exposure, as seen in chronic infections or autoimmune diseases, can lead to the development of exhausted B cells, characterized by this phenotype. Primary Immunodeficiencies: Abnormal levels may be observed in conditions affecting B cell development or function, such as: Common variable immunodeficiency (CVID) Specific antibody deficiency (SAD) Cancer: Alterations in this subset have been noted in certain hematologic malignancies, such as B cell lymphomas or leukemias, particularly those involving dysregulated B cell activation. Normal Ranges and Interpretation The percentage of activated CD21low CD38- B cells can vary based on age, health status, and laboratory standards. In healthy individuals, this subset typically represents a small proportion of the total B cell population. Significant deviations from normal ranges require careful interpretation in the context of clinical findings and other laboratory markers. Elevated Levels: May indicate chronic immune activation, autoimmune pathology, or B cell exhaustion. Decreased Levels: Rarely observed but could suggest impaired B cell activation or production. Evaluation and Diagnostic Approach If activated CD21low CD38- % is abnormal, further evaluation should include: Flow Cytometry Panel: To assess additional B cell markers and characterize the broader B cell profile. Clinical Correlation: A thorough review of symptoms, medical history, and underlying conditions. Additional Testing: Depending on suspected pathology, testing for autoimmune markers, chronic infections, or immunodeficiency conditions may be warranted. Conclusion The Activated CD21low CD38- % biomarker provides valuable insights into immune system status, particularly in the context of chronic activation, autoimmune diseases, or immune exhaustion. Its interpretation requires integration with clinical findings and other laboratory results to guide diagnosis and treatment strategies effectively.
Activated CD21low CD38- B Cells and Their Antibodies: Markers of Chronic Immune Activation Activated CD21low CD38- B cells are a distinct subset of B lymphocytes linked to chronic immune activation and immune dysregulation. These cells are characterized by: Low CD21 expression: A complement receptor involved in B cell activation and antigen binding. Absence of CD38: A marker typically associated with B cell activation and differentiation. Elevated activation markers: Such as CD80 and CD86. Increased inhibitory receptors: Including PD-1 and FCRL4. Antibodies Produced by CD21low CD38- B Cells Isotypes: Primarily class-switched antibodies (e.g., IgG, IgA). Specificity: Includes autoreactive antibodies and those targeting persistent antigens. Affinity: May exhibit reduced affinity maturation due to impaired participation in germinal centers. Functional Significance These cells and their antibodies are associated with: Chronic activation: Linked to persistent antigen exposure and inflammation. Exhaustion-like phenotype: Similar to exhausted T cells, they show reduced responsiveness to BCR and CD40 signaling. Cytokine production: Secrete pro-inflammatory cytokines, including IL-6 and TNF-α. Clinical Associations Autoimmune diseases: Systemic lupus erythematosus (SLE). Rheumatoid arthritis (RA). Sjögren's syndrome. Chronic infections: HIV, hepatitis C virus (HCV), malaria. Primary immunodeficiencies: Common Variable Immunodeficiency (CVID). Age-related immune dysfunction. Recent Research Developments Single-cell analysis: Highlights heterogeneity within the CD21low CD38- population. Epigenetic studies: Explore regulation of this subset's development and function. Therapeutic targeting: Investigating approaches to modulate or deplete these cells in autoimmune conditions. Diagnostic and Therapeutic Implications Monitoring activated CD21low CD38- B cells and their antibodies offers valuable insights into: Chronic immune activation and disease progression in autoimmune disorders and infections. Efficacy of immunomodulatory therapies. Potential biomarkers for immune exhaustion or dysregulation. Conclusion Activated CD21low CD38- B cells and their antibodies are critical markers of chronic immune activation and immune dysregulation, playing key roles in autoimmune diseases, chronic infections, and primary immunodeficiencies. Their presence and function provide essential diagnostic and therapeutic insights, though interpretation must account for the broader immune context and clinical presentation.